Amgen

Open: 287.71 Close: 283.7 Change: -4.01

The unbelievably easy way to evaluate Amgen: Use an AI.

The game is changing. There is a new strategy to evaluate Amgen fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, Inc, status, Amgens, stock, price, Feb, and the …

Concept Map

Semantic Network

Stock Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's products include Enbrel, Prolia, Xgeva, Otezla, Aranesp, and Repatha..

Today's Summary

Goldman Sachs continues to hold a Buy rating for Amgen. Wall Street analysts forecast AMGN stock price to rise over the next 12 months. Amgen expected to release earnings on 06 Feb 2024.

Today's News

Amgen Inc. per Employee $1.049M P/E Ratio 22.72 EPS $12.48 Yield 3.17% Dividend $2.25 Ex-Dividend Date Feb 15, 2024 Short Interest 9.3M 01/31/24 % of Float Shorted 1.74% Average Volume 2.71M Performance 5-day -2.55% -.11ioyx Grantdies Everyone economic secretaryoya African Slowly extendingwei Amgen is seeking a Regulatory Affairs Director supporting products in the Inflammation and Rare Disease Therapeutic Area. The role of the regulatory affairs director is to lead GRTs within Amgens GRAAS. BioAge acquired azelaprag from Amgen four months later, in April 2021. Amgen vets launch Latigo biotherapeutics to develop nonopioid pain relief. Amgen Inc. is down 1.86% at $290.70 per share. Goldman Sachs continues to hold a Buy rating for Amgen. This is Amgens third round of layoffs this year. The company also plans to cut its CEOs salary by 40% in an effort to save cash. The cuts will be focused primarily on its chemistry, manufacturing and controls division. Amgen is an Equal Opportunity Employer and will consider you without regard to your race, color, religion, sex, sexual orientation, gender identity, national origin, protected veteran status, or disability status. Join us as IS Engineer – Network Engineering. Amgen is an Equal Opportunity Employer and will consider all qualified applicants for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, protected veteran status, or disability status. Scam Advisory: Special Advisory: Please be cautious of scam recruitment offers. Wall Street analysts forecast AMGN stock price to rise over the next 12 months. Wall Street is overvalued by 15% compared to the current market price. Amgen Inc. (AMGN) stock price, quote & news - stock analysis. Amgen expected to release earnings on 06 Feb 2024 after the market closes (AMC) Investors would be looking at Amgens plans to take on current leaders in the weight loss. Amgen Inc. will present at the 34th Annual Oppenheimer Healthcare Life Sciences Conference at 12:00 p.m. Jan. 9, 2024. Amgen announced financial results for the fourth quarter and full year 2023 versus comparable periods.

Stock Profile

"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California."

Keywords

Are looking for the most relevant information about Amgen? Investor spend a lot of time searching for information to make investment decisions in Amgen. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, Inc, status, Amgens, stock, price, Feb, and the most common words in the summary are: amgen, market, stock, development, price, amgn, inc, . One of the sentences in the summary was: Wall Street analysts forecast AMGN stock price to rise over the next 12 months. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #amgen #market #stock #development #price #amgn #inc.